CRISPR Therapeutics Aktie
40,60
EUR
+0,80
EUR
+2,01
%
41,85
USD
+0,39
USD
+0,94
%
Werbung
CRISPR Therapeutics Aktie Analyse
26.07.19 | CRISPR Therapeutics Buy | Canaccord Adams | |
30.11.18 | CRISPR Therapeutics Buy | Needham & Company, LLC | |
15.05.18 | CRISPR Therapeutics Buy | Chardan Capital Markets | |
28.03.17 | CRISPR Therapeutics Buy | Chardan Capital Markets | |
14.11.16 | CRISPR Therapeutics overweight | Barclays Capital |
Werbung